From Molecular Classification to Targeted Therapeutics: The Changing Face of Systemic Therapy in Metastatic Gastroesophageal Cancer

@inproceedings{Murphy2015FromMC,
  title={From Molecular Classification to Targeted Therapeutics: The Changing Face of Systemic Therapy in Metastatic Gastroesophageal Cancer},
  author={Adrian G. Murphy and Ronan Joseph Kelly},
  booktitle={Gastroenterology research and practice},
  year={2015}
}
Histological classification of adenocarcinoma or squamous cell carcinoma for esophageal cancer or using the Lauren classification for intestinal and diffuse type gastric cancer has limited clinical utility in the management of advanced disease. Germline mutations in E-cadherin (CDH1) or mismatch repair genes (Lynch syndrome) were identified many years ago but given their rarity, the identification of these molecular alterations does not substantially impact treatment in the advanced setting… CONTINUE READING
1
Twitter Mention

Citations

Publications citing this paper.

References

Publications referenced by this paper.
SHOWING 1-10 OF 156 REFERENCES

J

H.E.R. Ford, A. Marshall
  • A. Bridgewater et al., “Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial,”The Lancet Oncology, vol. 15, no. 1, pp. 78–86
  • 2014
VIEW 5 EXCERPTS
HIGHLY INFLUENTIAL

C

M. Martin-Richard, R. Gallego
  • Pericay et al., “Multicenter phase II study of oxaliplatin and sorafenib in advanced gastric adenocarcinoma after failure of cisplatin and fluoropyrimidine treatment. A GEMCAD study,” Investigational New Drugs, vol. 31, no. 6, pp. 1573–1579
  • 2013
VIEW 5 EXCERPTS
HIGHLY INFLUENTIAL

K

Z. Lei, I. B. Tan
  • Das et al., “Identification of molecular subtypes of gastric cancer with different responses to pi3-kinase inhibitors and 5-fluorouracil,” Gastroenterology, vol. 145, no. 3, pp. 554–565
  • 2013
VIEW 6 EXCERPTS
HIGHLY INFLUENTIAL

D

S. Rao, N. Starling
  • Cunningham et al., “Matuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine alone as first-line treatment in patients with advanced oesophago-gastric cancer: a randomised, multicentre open-label phase II study,” Annals of Oncology, vol. 21, no
  • 2010
VIEW 4 EXCERPTS
HIGHLY INFLUENTIAL

S

P. Conrotto, D. Valdembri
  • Corso et al., “Sema4D induces angiogenesis throughMet recruitment by Plexin B1,” Blood, vol. 105, no. 11, pp. 4321–4329
  • 2005
VIEW 3 EXCERPTS
HIGHLY INFLUENTIAL

and P

A. Calles, N. Kwiatkowski, B. K. Cammarata, D. Ercan, N. S. Gray
  • A. Jänne, “Tivantinib (ARQ 197) efficacy is independent of MET inhibition in non-small-cell lung cancer cell lines,”Molecular Oncology, vol. 9, no. 1, pp. 260–269
  • 2015
VIEW 1 EXCERPT